Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis.
about
Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activitySelective non-steroidal glucocorticoid receptor agonists attenuate inflammation but do not impair intestinal epithelial cell restitution in vitroCompound A, a dissociated glucocorticoid receptor modulator, inhibits T-bet (Th1) and induces GATA-3 (Th2) activity in immune cellsDifferential cytokine profiles upon comparing selective versus classic glucocorticoid receptor modulation in human peripheral blood mononuclear cells and inferior turbinate tissueEvaluation of the selective glucocorticoid receptor agonist compound A for ototoxic effectsNoise trauma and systemic application of the selective glucocorticoid receptor modulator compound A.Influence of short-term glucocorticoid therapy on regulatory T cells in vivo.Preventive treatment with methylprednisolone paradoxically exacerbates experimental autoimmune encephalomyelitis.Effect of the plant derivative Compound A on the production of corticosteroid-resistant chemokines in airway smooth muscle cells.Chemokine-mediated redirection of T cells constitutes a critical mechanism of glucocorticoid therapy in autoimmune CNS responses.GR-independent down-modulation on GM-CSF bone marrow-derived dendritic cells by the selective glucocorticoid receptor modulator Compound A.Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and AP-1.Eosinophil resistance to glucocorticoid-induced apoptosis is mediated by the transcription factor NFIL3.Novel Drug Delivery Systems Tailored for Improved Administration of Glucocorticoids.Compound A influences gene regulation of the Dexamethasone-activated glucocorticoid receptor by alternative cofactor recruitment.Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential.Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.Compound A, a selective glucocorticoid receptor agonist, inhibits immunoinflammatory diabetes, induced by multiple low doses of streptozotocin in mice.Selective glucocorticoid receptor modulation maintains bone mineral density in mice.Deletion of the Mineralocorticoid Receptor in Myeloid Cells Attenuates Central Nervous System Autoimmunity.Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism.Effect of combining glucocorticoids with Compound A on glucocorticoid receptor responsiveness in lymphoid malignancies.
P2860
Q26782111-F2E5DA64-AF96-4AA7-B101-F0745E000FBEQ28479065-08AA2B8B-91FB-416C-A2B3-C34457057659Q28482191-6D41E0E2-6AA8-45AA-86C4-728E19F36C27Q28546223-BF334DBE-59B2-461F-8AAB-799C9CC9CD0FQ30382813-4BA6D7AA-1F97-45E8-8022-424945E05347Q30383830-F1F6F22A-AE9D-4391-B4E1-B9375CC913BFQ34017908-A34DDF71-E352-4BF6-AC5D-153DD37704EFQ36454930-178A998A-6CA9-462E-8D25-0CA8F7614A63Q36549178-4DBC6F87-CABD-40F2-B1B3-45B404C6CEB2Q37091531-BCA307C6-CDFF-4A08-A697-90934A7E148DQ37421622-74F07AA7-C54C-4D30-8090-86F63766D196Q37470723-44F5ECE9-6F58-4A27-A5AF-309D1647900CQ38417153-0420B2FD-0375-420F-B32F-6EC1504E9798Q38637805-B87F8F8D-2680-4521-9760-E81E05D40934Q38642503-CA8449D0-9B78-4AA8-94CB-B29112714A52Q38735389-05F11840-AC3C-484C-A533-F3DA30DBBF75Q39223255-D15245DA-4F34-4926-B359-F61C43D0E11FQ42030632-D7489FE1-CE74-45E9-BFB0-394E91EE4ECFQ43751384-2A2CED8E-6EE6-4015-9808-E1E7CB336D47Q47120039-FBFA3977-E8EB-4829-9075-D142F0F3C640Q55066536-6FD5DFCC-11D9-47EC-97AE-1CCF05984612Q55281041-CBC8073A-164C-48DA-9955-CE6E2F8661AE
P2860
Therapeutic and adverse effects of a non-steroidal glucocorticoid receptor ligand in a mouse model of multiple sclerosis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@ast
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@en
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@nl
type
label
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@ast
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@en
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@nl
prefLabel
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@ast
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@en
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@nl
P2093
P2860
P1433
P1476
Therapeutic and adverse effect ...... e model of multiple sclerosis.
@en
P2093
Christiane Menzfeld
Denise Tischner
Fred Lühder
Holger M Reichardt
Jan P Tuckermann
Jens van den Brandt
Michael John
Simone Wüst
P2860
P356
10.1371/JOURNAL.PONE.0008202
P407
P577
2009-12-07T00:00:00Z